Jens C. Eickhoff, Ph.D.
Affiliations: | 2002 | Iowa State University, Ames, IA, United States |
Area:
Statistics, Biostatistics BiologyGoogle:
"Jens Eickhoff"Parents
Sign in to add mentor| Yasuo Amemiya | grad student | 2002 | Iowa State | |
| (Generalized linear latent variable modeling analysis for multi -group studies.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Valentinuzzi D, Vrankar M, Boc N, et al. (2020) [18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab. Radiology and Oncology. 54: 285-294 |
| Uboha NV, Lubner SJ, LoConte NK, et al. (2020) Phase 1 dose escalation trial of TAS-102 (trifluridine/tipiracil) and temozolomide in the treatment of advanced neuroendocrine tumors. Investigational New Drugs |
| Uboha NV, Eickhoff JC, Chandrasekharan C, et al. (2020) Phase II study of the combination of abemaciclib and pembrolizumab in locally advanced unresectable or metastatic gastroesophageal adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149. Journal of Clinical Oncology. 38: TPS461-TPS461 |
| Uboha NV, Lubner SJ, LoConte NK, et al. (2020) Phase I dose-escalation trial of trifluridine/tipiracil (TAS-102) and temozolomide in the treatment of advanced neuroendocrine tumors. Journal of Clinical Oncology. 38: 615-615 |
| Deming DA, Emmerich P, Turk AA, et al. (2020) Pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver oligometastatic MSS/MMR proficient colorectal cancer (CRC). Journal of Clinical Oncology. 38: 4046-4046 |
| Uboha NV, Maloney JD, McCarthy D, et al. (2019) Phase I/II trial of perioperative avelumab in combination with chemoradiation in the treatment of stage II/III resectable esophageal cancer. Journal of Clinical Oncology. 37: TPS181-TPS181 |
| Turk AA, Lubner SJ, Uboha NV, et al. (2019) A phase Ib study of pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver metastatic colorectal cancer (CRC). Journal of Clinical Oncology. 37: 680-680 |
| Bassetti MF, Turk AA, Lubner SJ, et al. (2019) A phase Ib study of pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver metastatic MSS colorectal cancer (CRC): A postoperative safety analysis. Journal of Clinical Oncology. 37: e15047-e15047 |
| Liu G, Fong L, Antonarakis ES, et al. (2019) Randomized phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) versus GM-CSF adjuvant in patients with PSA-recurrent prostate cancer. Journal of Clinical Oncology. 37: 5037-5037 |
| Uboha NV, Maloney JD, McCarthy D, et al. (2019) Safety of neoadjuvant chemoradiation (CRT) in combination with avelumab (A) in the treatment of resectable esophageal and gastroesophageal junction (E/GEJ) cancer. Journal of Clinical Oncology. 37: 4041-4041 |